Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Seltorexant in Recreational Sedative Users
NCT05106153Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of seltorexant in major depressive disorder (MDD) and insomnia disorder (12 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale at 24 hours. Started Dec 2021; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)insomnia disorder
Beyond the preview
Go deeper on NCT05106153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106153.